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Pancreatic cancer remains as one of the most aggressive human neoplasms, with overall poor survival rates. Radical
surgery of the primary lesion is the best option for treatment. Borderline resectable pancreatic tumors (BRPT),
defined as partial involvement of peripancreatic vasculature, may benefit from neoadjuvant therapy. We report on
the first two BRPT cases treated with neoadjuvant chemoradiation at our institution. Preoperative CT and MRI
demonstrated pancreatic tumors encasing the porto-mesenteric confluence suggestive of BRPT. Patients received
neoadjuvant chemotherapy (gemcitabine/cisplatin), followed by radiochemotherapy. After treatment, follow-up
images demonstrated tumor downsize, allowing for the tumors to be considered then as resectable. They
underwent partial pancreatoduodenectomies (Whipple procedure). In case 1, histopathology revealed a complete,
margin-free resection, whereas in case 2 there was a complete pathological response, with no evidence of residual
tumor. According to the literature, our initial experience using neoadjuvant chemoradiotherapy on BRPT allowed us
to downsize the tumor and, subsequently, to perform a curative surgery.
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Pancreatic adenocarcinoma remains as one of the most
devastating human cancers, with an overall 5-year sur-
vival of <5% [1]. Most patients are diagnosed with
advanced disease and only 10 to 20% of patients are re-
sectable at the time of diagnosis [2]. Radical surgery (R0
resection) of the primary tumor and regional lymph
node dissection offers the only chance of long-term sur-
vival, but unfortunately the majority of those patients
treated with curative surgical resection will eventually
recur regionally or develop distant metastases [3,4].
Pancreatic tumors can be classified as resectable (stage
I or II), locally advanced (stage III), or metastatic (stage
IV). However, with recent advances in pancreatic im-
aging and surgical techniques, a distinct subset of
tumors is emerging that blurs the distinction between
resectable and locally advanced disease: tumors of* Correspondence: jamartin@med.puc.cl
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reproduction in any medium, provided the or‘borderline resectability’ [5]. This group includes tumors
that exhibit encasement of a short segment of the hep-
atic artery, without evidence of tumor extension to the
celiac axis (CA) and tumor abutment of the superior
mesenteric artery (SMA) involving <180° of the circum-
ference of the artery; or short-segment occlusion of the
superior mesenteric vein (SMV), portal vein (PV), or
their confluence [5]. There is no consensus regarding
the management of borderline resectable pancreatic
tumors (BRPT). Several studies have suggested that the
margin resection status is a very important prognostic
factor and that a margin-positive resection strongly
predicts early recurrence and short survival [5-8].
Neoadjuvant therapy of BRPT potentially can increase
the likelihood of a margin-free resection. Also, it can
serve as a biological marker of response to treatment
[6]. We report our first two BRPT cases treated ini-
tially with neoadjuvant chemoradiation and subse-
quent radical surgery.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Case 1
A 58-year-old man presented with weight loss, jaundice
and abdominal pain. Laboratory parameters were com-
patible with obstructive jaundice. CA19-9 was elevated
(214 UI/mL). MRI demonstrated a solid tumor at the
pancreatic neck. The axial diameter of the tumor was
2.2 cm, encasing the porto-splenic-mesenteric con-
fluence (>180°), with SMV compromise of 18 mm (longi-
tudinal axis) and without compromise of CA and SMA
(Figure 1A,B). There was no evidence of lymph node
involvement or metastatic disease. An endoscopic
ultrasound-guided fine needle aspiration biopsy was
obtained. Pathology revealed a well-differentiated pan-
creatic adenocarcinoma. At the same time a biliary stent
was placed. The patient received three cycles of chemothe-
rapy (gemcitabine: 1,000 mg/m2 and cisplatin: 50 mg/m2)
every two weeks. He also commenced radiotherapy
(50.4 Gy in 30 fractions) and infusional 5-fluorouracil
(200 mg/m2). The dose had to be reduced by 20% due to
thrombocytopenia. At the end of treatment, CA19-9
dropped to 124 UI/mL. Follow-up MRI demonstrated
further reduction in local disease, with no evidence of
porto-mesenteric infiltration (Figure 1C,D). Based on
his remarkable response the decision was made to ex-
plore the patient, so he underwent a Whipple procedure
with curative intention.
Histopathological analysis of the specimen demon-
strated a 1.5 cm, moderately differentiated pancreatic
adenocarcinoma with extensive signs of regression, with
multiple microscopic infiltrative foci (Figure 2). Surgical
margins were free of disease.Figure 1 MRI of solid tumor at the pancreatic neck in Case 1. (A,B) Ini
adenocarcinoma (arrow). The tumor is encasing the porto-mesenteric conf
regression in the axial diameter of the tumor (arrow) and patency of the PCase 2
A 72-year-old man presented with a history of abdom-
inal pain, jaundice and weight loss. Laboratory results
demonstrated a cholestatic pattern. CA19-9 was 37.8
UI/mL. Diagnostic studies revealed a 1.8 cm pancreatic
mass, encasing the porto-splenic confluence (>180°) with
attachment to the SMA (<180°) (Figure 3A,B). Unfortu-
nately, it was not possible to perform a needle biopsy
due to technical difficulties. However, images were ana-
lyzed by a group of expert radiologists and evaluated
with a multidisciplinary team composed of oncologists,
gastroenterologists and HPB surgeons, who agreed in
the diagnosis of pancreatic cancer.
A biliary stent was placed, and relief of jaundice was
achieved. He then commenced chemotherapy with gem-
citabine (1,000 gm/m2) in combination with cisplatin
(50 mg/m2) every two weeks. The patient completed
three cycles of chemotherapy. During chemotherapy,
cross sectional imaging suggested partial tumor regres-
sion, with increased patency of PV (compromise <180°)
and less compromise of SMA (<90°), with no evidence
of metastatic disease. The patient was referred for con-
solidation radiotherapy, of which he had a total of 50.4 Gy
in 30 fractions and infusional 5-fluorouracil (200 mg/m2).
He developed no major adverse effects.
Follow-up CT demonstrated reduction in local disease
(Figure 3C,D). Eleven months after the initial diagnosis
the patient underwent surgery with curative intent in
the form of a Whipple procedure. He had an uneventful
recovery period.
The whole pancreatic specimen was sent for patho-
logical examination, processed in blocks of 3 to 4 mmtial MRI, showing a hypovascular pancreatic tumor compatible with
luence (arrowheads); (C,D) MRI after neoadjuvant therapy. It shows a
V and SMV (arrowheads).
Figure 2 Histopathology review. (A) Pancreatic epithelium infiltrated by adenocarcinoma with large signs of regression (white arrows) (60x);
(B) Tumor regression, which consists in multiple microscopic foci of infiltration into the macroscopic nodular area (black arrow) (100x).
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tumor. Sixteen paraffin blocks, 18 slides and 19 sections
were reviewed. Further immunohistochemistry failed to
confirm a pancreatic carcinoma. These findings were
considered as a complete pathological response (Figure 4).
Discussion
Pancreatic cancer is a devastating malignancy with a 5-
year overall survival of about 4% [1]. Margin-free resec-
tion of the tumor is considered the only chance of cure
for these patients, although only 10 to 20% of the
tumors are deemed to be resectable at the time of diag-
nosis. For most patients, curative surgery is not possible
because of systemic metastases, advanced nodal disease
or a localized tumor that is not amenable of resection
due to invasion of adjacent vital structures [2].
Recently, the designation of borderline resectable
tumors has emerged to describe a subpopulation of
potentially resectable tumors. For tumors of the head
or uncinate process, these criteria include SMV/PV
compromise, SMA abutment, encasement of theFigure 3 Abdominal CT images for Case 2. (A,B) Abdominal CT at the ti
pancreatic tumor encasing the porto-splenic confluence (arrow) and attach
therapy shows local disease reduction, with increased permeability of the Pgastroduodenal artery up to its origin at the hepatic
artery, limited inferior vena cava involvement, short-
segment SMV occlusion, and colon or mesocolon
invasion [5].
Patients with borderline resectable tumors treated with
surgical resection alone can be expected to have a higher
rate of local and systemic disease recurrence and worse
survival compared with patients who presented with ini-
tially resectable disease. This may be related to technical
aspects (more difficult surgery), the advanced nature of
the tumor, and the high risk for margin-positive
resection. Therefore, the goal in the management of the
borderline resectable patient is to maximize the chance
of a complete resection, which may be accomplished by
the use of neoadjuvant therapy [7].
The role of neoadjuvant therapy in borderline resect-
able disease is a highly debated topic [8,9]. This modality
of treatment may allow tumor downsizing, reduce the
incidence of positive resection margins, delivery of treat-
ment to intact well-vascularized tissues, and higher rates
of treatment completion. Also, it facilitates selection forme of diagnosis, showing a pancreatic node compatible with a
ment to the SMA (arrowhead); (C,D) Control CT after neoadjuvant
V (arrow) and less compromise of SMA (arrowhead).
Figure 4 Immunohistochemical analysis of Case 2. (A) At low power, dilated pancreatic duct with normal epithelium is seen. At the lower left
corner a pancreatic lesion with a few atypical secondary ducts is observed (arrow head); (B) At medium power, a few atypical ducts with a
desmoplastic-like surrounding stroma is seen; (C) At high power, ducts are lined by irregular epithelium, with micronucleoli and irregular
chromatin cells nuclei, suggestive but not consistent with carcinoma; (D) Ki-67 labeling shows nuclear reaction in less than 1% of the cells.
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Patients who do not develop progressive disease prior to
rescue surgery or patients with significant downsize
response may have a better prognosis, and moreover,
those with poor tumor biology are selected out via
disease progression, thereby avoiding the morbidity of
futile surgery [10].
Katz et al. reported on a group of patients with
borderline resectable pancreatic adenocarcinoma treated
with neoadjuvant chemoradiotherapy; 125 patients
received this modality of treatment. Of these, 66
(41%) underwent pancreatectomy. Negative margin was
obtained in 94% of the cases. Median survival was 40
months for patients who completed all therapy and 13
months for patients who did not undergo surgery [11].
McClaine et al. reported a 46% rate of surgical resection
in a cohort of 26 patients with borderline pancreatic
adenocarcinoma who underwent neoadjuvant chemora-
diotherapy; 67% of them had a margin free resection.
Median survival for resected patients was 23.3 months
vs. 15.5 months for non-resected cases [12]. These two
studies included a different number of patients; however,
the difference was statistically significant in both. In ano-
ther study, Brown et al. reported a cohort of 13 patients
with borderline pancreatic adenocarcinoma who received
neoadjuvant therapy. In 11 of 13 patients a margin-
negative resection was achieved and nine patients were
alive at 20 months follow-up [13]. A systematic review
analyzed the role of neoadjuvant chemoradiotherapy for
the treatment of both resectable and initially labeled asunresectable pancreatic cancer [14]. This study demon-
strated that patients with unresectable pancreatic can-
cer who underwent neoadjuvant chemoradiotherapy
achieved comparable 1-year survival as those with ini-
tially resectable disease; 40% of borderline or unresect-
able cases were ultimately resected. Also, it was not
associated with a statistically significant increase in the
rate of pancreatic fistula or overall complications in the
chemoradiation group.
Conclusions
Our initial experience in these two cases with borderline
resectable tumors treated with neoadjuvant chemoradia-
tion is encouraging. We recognize that the decision to
offer this modality of treatment not having a biopsy
suggestive of pancreatic adenocarcinoma (Case 2) might
be debatable, but at the same time we believe that its
radiological response made a neoplasm the most likely
diagnosis, considering that other etiologies, such as
chronic pancreatitis, should not be affected by chemora-
diation. In any case, these results are consistent with the
published literature, suggesting a clear benefit in terms
of curative surgical resection. At this time our center is
actively enrolling more patients to be considered for this
modality of treatment.
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